Physician profile
Mark E Poplawski
NPI 1629147624
$598.63
in general payments reported to CMS, 2019-2025
10 companies · $32.34 in 2025
The $32.34 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.20 · 2022: $73.07 · 2023: $93.11 · 2024: $320 · 2025: $32.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $191.76 | 2021-2024 | Intellis Adaptivestim |
| Amgen INC. | $124.99 | 2024 | Krystexxa |
| Nevro Corp. | $104.61 | 2022-2024 | Senza |
| Organogenesis INC. | $55.79 | 2023-2024 | Puraply |
| Angiodynamics, INC. | $32.35 | 2024 | Auryon Laser System 100-120 Vac |
| Paratek Pharmaceuticals, INC. | $32.34 | 2025 | Nuzyra |
| Synergy Orthopedics, LLC | $17.32 | 2023 | |
| Horizon Therapeutics Plc | $14.26 | 2023 | Krystexxa |
| Acera Surgical, INC. | $13.08 | 2022 | |
| Integra Lifesciences Corporation | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Poplawski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.